| Literature DB >> 30643531 |
Dalin Chen1, Hongliang Li2, Wen Li1, Shuo Feng1, Dingsen Deng1.
Abstract
Kaempferia parviflora (KP), a health-promoting herb, has been traditionally used for treating a variety of diseases. Pharmacological studies have claimed the various benefits from KP and its main effective methoxyflavones, including cellular metabolism-regulating activity, anticancer activity, vascular relaxation and cardioprotective activity, sexual enhancing activity, neuroprotective activity, antiallergic, anti-inflammatory, and antioxidative activity, antiosteoarthritis activity, antimicroorganism activity, and transdermal permeable activity. These might be associated with increased mitochondrial functions and activated cGMP-NO signaling pathway. However, the underlying molecular mechanisms of KP and its methoxyflavones are still under investigation. The clinical applications of KP and its methoxyflavones may be limited due to their low bioavailability. But promising strategies are on the way. This review will comprehensively discuss the biological activities of KP and its methoxyflavones.Entities:
Year: 2018 PMID: 30643531 PMCID: PMC6311295 DOI: 10.1155/2018/4057456
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Picture of KP rhizomes (left) and identified structure of methoxyflavones (right) isolated from KP. The main structure of methoxyflavone includes benzene A ring with 2 substituent groups at positions 5 and 7, an aromatic B ring with 2 substituent groups at positions 3′ and 4′, and C ring with a substituent group linking on position 3. The substituent groups might be -H, -OH, or -OCH3.
The biological activities of KP and its methoxyflavones.
| Activities | Extracts/compounds | Models | Doses | Biological activities | Ref. |
|---|---|---|---|---|---|
| Metabolism regulation | Ethanol KP extract: modified starch (3:7) for powder. | Male ddY mice, | 45mg/kg/day, | Improve physical fitness performance and muscular endurance, increase PGC-1 | [ |
| Methanol KP extract dissolved in DMSO | 3T3-L1 | 3, 10, and 30 | Activate ATGL/HSL/PPAR | [ | |
| Compound | 3T3-L1 | 5, 15, and 30 | |||
| 50% ethanol extract was freeze-dried for powder | C57BL6J mice | HFD containing 0.5% or 1% KP extract for 7 weeks | Increase UCP1 expression, activate BAT. | [ | |
| KP rhizome was pulverized with a Wonder Blender for KP powder | TSOD mice | 1% and 3% KP powder in powder feed MF | Suppress body weight increase, visceral fat accumulation, hypertension, hyperinsulinemia, glucose intolerance, peripheral neuropathy, lipid metabolism abnormalities, and insulin resistance. | [ | |
| Ethyl acetate KP extract dissolved in DMSO | 3T3-L1 | 1 and 3 | Upregulate C/EBP | [ | |
| Compound | 3T3-L1 | 3, 10, and 30 | |||
| Ethyl acetate KP extract was pulverized for KP powder | TSOD mice, | 0.3% and 1% KP mix with MF for 8 weeks | Upregulate PPAR | [ | |
| Ethyl acetate KP extract | Brown adipocytes | 1, 3, 10, and 30 | |||
| 70% ethanol KP extract dissolved in DMSO | pC2C12 dC2C12 | 1, 3, and 10 | Upregulate the expression of GLUT4, MCT1, and PGC-1 | [ | |
| Compound | 1 and 10 | ||||
| 95% ethanol KP extract | C57BL/6J | 200 mg/kg/day + HFD for 10 weeks | Increase PGC-1 | [ | |
| L6 myotubes | 1 and 10 | Upregulate Sirt1/AMPK/PPAR | |||
| 95% ethanol KP extract was prepared by lyophilization | Male mice | 250 mg/kg KP extract in carboxymethyl cellulose for 7, 14, 21 days | Increase CYP1A1, CYP1A2, CYP2B, and CYP2E1 activities, but CYP3A not change. | [ | |
| 60% ethanol KP extract mixed with dextrin for dried powder | volunteers | 100 mg in a pullulan capsule | Increase whole-body energy expenditure. | [ | |
|
| |||||
| Anti-cancer | 95% ethanol KP extract was prepared for freeze-dried powder dissolved in DMSO | U937 | 20, 40, 60, 80, and 100 | Inhibit proliferation and viability, increase apoptosis | [ |
| Methanol extract was partitioned into EtOAc-soluble fraction and methanol fraction | B16 melanoma 4A5 | 1, 2.5, 5, and 10 | Inhibit melanogenesis with IC50 = 9.6 and 4.9 | [ | |
| Compound | B16 melanoma 4A5 | 3,10, and 30 | Inhibit melanogenesis, suppress tyrosinase, TRP-1, and TRP-2 expression. | [ | |
| 95% ethanol KP extract was prepared by lyophilization and dissolved in DMSO | HeLa | 10, 50, and 100 | Suppress PI3K/AKT and MAPK signaling, inhibit migration and invasion, inhibit MMP-2 expression | ||
| Tincture, ethanol, or aqueous extract and Compound | LLC-GA5- | 1, 5, 10, 50, and 100 | Increase the accumulation of rhodamine 123 and daunorubicin | [ | |
| Tincture, ethanol, or aqueous extract and Compound | A549 | 0.3-100 | Accumulate calcein and doxorubicin | [ | |
| Ethanol extract (no details in preparation) | aortic ring | 10 and 100 | Antagonize PE- or ACH-induced contraction. | [ | |
|
| |||||
| Vascular relaxation and cardioprotection | 95% ethanol KP extract dried under vacuum was dissolved in DMSO | HUVEC | 1 and 10 | Upregulate the expression of eNOS and NO | [ |
| Dichloromethane fraction of KP ethanol extract | middle-aged male rats | 100 mg/kg twice a day for 6 weeks | Decrease contraction to phenylephrine, increase vasorelaxation to acetylcholine. | [ | |
| 95% ethanol KP extract was prepared by lyophilization suspended in 15% Tween-20 | aortic ring | 1, 10, and 100 | Reduce superoxide anion | [ | |
| 95% ethanol KP extract was prepared by lyophilization suspended in 15% Tween-20 | aortic ring | 1, 10, and 100 | Upregulate cGMP-NO signaling, inhibit Ca2+ influx, and reduce ROS | [ | |
| Upregulate eNOS and CSE expression and downregulate NO and H2S production. Low down plasma glucose and elevate HDLC levels. | [ | ||||
| 70% methanol extract was lyophilized to dried extract and was suspended in 50 % propylene glycol aqueous solution | DIC rats | 200 and 500 mg/kg for 7 successive days | prolong euglobulin lysis time, activate fibrinolysis | [ | |
| Saline extract was filtered with Whatman filtered paper NO.1 | Swine heart | 12.5, 25, 50 and 100 mg/kg | Increase DFT and ULV, attenuate diastolic and systolic blood pressures. | [ | |
| Saline extract was filtered with Whatman filtered paper NO.1 | normal rat heart | 12.5 and 100 mg/kg | Upregulate cGMP-NO signaling and downregulate Ca2+ transient. | [ | |
| Compound | aortic ring | 10, 30, and 100 | Induce vasorelaxation, activate NO-eGMP, increase K+ efflux, and attenuate Ca2+ influx. | [ | |
| The water-soluble powder of KP suspended in Tween 80 (no details in preparation for dried powder) | STZ-induced diabetic rats | 140, 280, and 420 mg/kg | Increase serum testosterone levels, sperm concentration, teste weight, and improve sexual performance. | [ | |
|
| |||||
| Sexual enhancement | Ethanol, hexane, and water extract prepared with polyvinylpyrrolidone (PVP) | SD rats | 10, 20, and 40 mg/kg for 5 weeks | Only ethanol extract increases the blood flow to the testis. | [ |
| Ethanol extract was evaporated under reduced pressure until dried dissolved in DMSO | PDE-5 from mouse lung | 50 | Show 62.63% inhibitory effect (IC50=12.24 | [ | |
| Compound | PDE-5 from mouse lung | 10 | IC50 = 10.64±2.09 | [ | |
| Compound | Isolated human cavernosum | 0.1 and 0.3 mM | Inhibit L-type Ca2+ channel, induce immobilization of Ca2+. | [ | |
| Compound | AChE, BChE | 0.1 mg/mL | Inhibit the activity of AChE and BChE | [ | |
|
| |||||
| Neuroprotection | Ethanol extract was dissolved in 2% Tween 80 | SD rats | 200 mg/kg | Increase NE, 5-HT, and DA production, increase GFAP and DPYSL2 expression. | [ |
| Compound | Recombinant human BACE1 | 3, 30, 50, and 100 | inhibit BACE1 activity (IC50= 5.98×10-5M, 3.69×10-5M, and 4.95×10-5M, respectively) | [ | |
| 95% ethanol KP extract dissolved in 0.5% carboxymethycellulose | Rats | 100 mg/kg | Improve spatial memory and cells proliferation damaged by VPA. | [ | |
|
| RBL-2H3 | 125, 250, 500 | Inhibit degranulation; Inhibit the productions of TNF | [ | |
|
| |||||
| anti-allergy | Compound | RBL-2H3 | 50 | Inhibit degranulation; Inhibit the productions of TNF | [ |
| Ethanol extract was partitioned by hexane, chloroform, ethyl acetate, and water fractions and evaporated to dryness in vacuo | RAW264.7 | 3, 10, 30, and 100 | |||
| Compound | RAW264.7 | 3, 10, 30, and 100 | Inhibit PGE2 and iNOS expression. | [ | |
| Compound | RAW264.7 | 3, 10, 30, and 100 | Inhibit the release of NO (IC50=16.1 | [ | |
| Chloroform fraction and ethanol extract were evaporated to dryness in vacuo | RAW264.7 | 1,3, 10, 30, and 100 | Inhibit NO release with IC50 value of 8.4 and 8.1 | [ | |
| Compound | RAW264.7 | 3, 10, and 30 | Inhibit NO release with IC50 value of 5.1, 4.6, and 8.7 | [ | |
| 50% ethanol extract | RAW264.7, THP-1 | 250, 500, and 1000 | Decrease NO levels, inhibit THP-1 adhesive activity and CAMs and inflammatory cytokines expression, and ameliorate oxidative stress. | [ | |
| Compound | Rat chondrocytes | 5, 10, and 20 | Decrease IL-1 | [ | |
|
| |||||
| Anti-osteoarthritis | Ethanol extract | TSOD mice | 1% KP mix with MF for 12 weeks | Decrease the thickness of subcutaneous fat layer and the infiltration of adipocytes into the dermis. Prevent against UVB-induced denaturation of collagenous fibers. | [ |
|
| |||||
| Transdermal permeation | Ethanol extract | Epididymis, BPH rat model | 100, 200, 500 | Inhibit 5 | [ |
|
| |||||
| Miscellaneous section | Compound | Epididymis | 50 | Inhibit 5 | [ |
| 70% methanol KP extract was prepared by lyophilization and dissolved in propylene glycol | Rat | 30, 60, and 100 mg/kg | Inhibit gastric ulcer induction, preserve gastric wall mucus, and exhibit no effects on gastric volume, acidity, and pH output. | ||
| 95% ethanol extract was concentrated under reduced pressure | 5-week-old female hairless mice | 100 and 200 mg/kg | Suppress UVB-induced MMP-2, -3, -9, -13 IL-1 | [ | |
| 95% ethanol extract was concentrated under reduced pressure | 8-week-old female hairless mice | 200mg/kg/day for 24 weeks; | Increase PGC-1 | [ | |
| 95% ethanol extract was concentrated under reduced pressure | Hs68 cells | 1, 5, and 10 | Increase PGC-1 | [ | |